Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
BCMA inhibitor
DRUG CLASS:
BCMA inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
elranatamab-bcmm (8)
JNJ-5322 (3)
teclistamab-cqyv (2)
CC-93269 (2)
CTX-8573 (1)
AMG 701 (1)
MK-4002 (1)
ABBV-383 IV (0)
CDR101 (0)
F182112 (0)
FT576 (0)
ISB 2001 (0)
MBS314 (0)
RO7297089 (0)
SAR445514 (0)
SCR-8572 (0)
TQB2934 (0)
WVT078 (0)
REGN5458 (0)
AMG 420 (0)
REGN5459 (0)
elranatamab-bcmm (8)
JNJ-5322 (3)
teclistamab-cqyv (2)
CC-93269 (2)
CTX-8573 (1)
AMG 701 (1)
MK-4002 (1)
ABBV-383 IV (0)
CDR101 (0)
F182112 (0)
FT576 (0)
ISB 2001 (0)
MBS314 (0)
RO7297089 (0)
SAR445514 (0)
SCR-8572 (0)
TQB2934 (0)
WVT078 (0)
REGN5458 (0)
AMG 420 (0)
REGN5459 (0)
›
Associations
(18)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
teclistamab-cqyv
Sensitive: A1 - Approval
teclistamab-cqyv
Sensitive
:
A1
teclistamab-cqyv
Sensitive: A1 - Approval
teclistamab-cqyv
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
elranatamab-bcmm
Sensitive: A1 - Approval
elranatamab-bcmm
Sensitive
:
A1
elranatamab-bcmm
Sensitive: A1 - Approval
elranatamab-bcmm
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
MK-4002
Sensitive: B - Late Trials
MK-4002
Sensitive
:
B
MK-4002
Sensitive: B - Late Trials
MK-4002
Sensitive
:
B
TNFRSF17-L
Multiple Myeloma
TNFRSF17-L
Multiple Myeloma
AMG 701
Sensitive: C3 – Early Trials
AMG 701
Sensitive
:
C3
AMG 701
Sensitive: C3 – Early Trials
AMG 701
Sensitive
:
C3
IL6-L
Multiple Myeloma
IL6-L
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
TNFRSF17 amplification
Multiple Myeloma
TNFRSF17 amplification
Multiple Myeloma
elranatamab-bcmm
Resistant: C3 – Early Trials
elranatamab-bcmm
Resistant
:
C3
elranatamab-bcmm
Resistant: C3 – Early Trials
elranatamab-bcmm
Resistant
:
C3
CCL3-L
Multiple Myeloma
CCL3-L
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
IL17C-L
Multiple Myeloma
IL17C-L
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
elranatamab-bcmm
Sensitive: C3 – Early Trials
elranatamab-bcmm
Sensitive
:
C3
TNFRSF17 positive
Multiple Myeloma
TNFRSF17 positive
Multiple Myeloma
teclistamab-cqyv
Sensitive: D – Preclinical
teclistamab-cqyv
Sensitive
:
D
teclistamab-cqyv
Sensitive: D – Preclinical
teclistamab-cqyv
Sensitive
:
D
TNFRSF17 underexpression
Multiple Myeloma
TNFRSF17 underexpression
Multiple Myeloma
CTX-8573
Sensitive: D – Preclinical
CTX-8573
Sensitive
:
D
CTX-8573
Sensitive: D – Preclinical
CTX-8573
Sensitive
:
D
TNFRSF17 expression
Multiple Myeloma
TNFRSF17 expression
Multiple Myeloma
CC-93269 + CC-220
Sensitive: D – Preclinical
CC-93269 + CC-220
Sensitive
:
D
CC-93269 + CC-220
Sensitive: D – Preclinical
CC-93269 + CC-220
Sensitive
:
D
TNFRSF17 expression
Multiple Myeloma
TNFRSF17 expression
Multiple Myeloma
CC-93269 + CC-92480
Sensitive: D – Preclinical
CC-93269 + CC-92480
Sensitive
:
D
CC-93269 + CC-92480
Sensitive: D – Preclinical
CC-93269 + CC-92480
Sensitive
:
D
GPRC5D expression
Multiple Myeloma
GPRC5D expression
Multiple Myeloma
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
TNFRSF17 expression
Multiple Myeloma
TNFRSF17 expression
Multiple Myeloma
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
TNFRSF17 expression + GPRC5D expression
Multiple Myeloma
TNFRSF17 expression + GPRC5D expression
Multiple Myeloma
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
JNJ-5322
Sensitive: D – Preclinical
JNJ-5322
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login